Amgen Reports Fourth Quarter And Full Year 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Amgen (AMGN) PT Raised to $202 at BMO Capital Amid Positive Repatha Data
February 3, 2017 6:53 AM ESTBMO Capital raised its price target on Amgen (NASDAQ: AMGN) to $202.00 (from $197.00) while maintaining a Outperform rating following positive Repatha CV outcomes data
Analyst M. Ian Somaiya commented, "Addition of CV outcomes data to the Repatha label and launch of erenumab for migraine... More
Amgen (AMGN) Tops Q4 EPS by 10c, Offers FY Guidance
February 2, 2017 4:23 PM ESTAmgen (NASDAQ: AMGN) reported Q4 EPS of $2.89, $0.10 better than the analyst estimate of $2.79. Revenue for the quarter came in at $5.97 billion versus the consensus estimate of $5.74 billion.
GUIDANCE:
Amgen sees FY2017 EPS of $11.80-$12.60, versus the consensus of $12.44. Amgen sees... More
